Q1FY27 Investor Presentation: Revenue Down 42% YoY, Guidance Moderated
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Ganesh Remedies reported weak Q1FY27. Revenue fell 42% YoY to Rs 14.36 Cr; PAT dropped 68% YoY to Rs 1.12 Cr. EBITDA margin compressed 624 bps to 23.3% on subdued European demand and order deferrals amid geopolitical uncertainty. EU distributor agreement terminated for non-performance, enabling direct customer access. CRAMS South-East Asia projects on track for revenue contribution from H2FY27. Management moderated earlier FY27 non-linear growth guidance citing timing issues. Block 7 commissioning and Dahej expansion plans remain intact.
Sharp YoY decline in revenue and profits; margin pressure and guidance cut are negatives. H2FY27 catalysts (CRAMS, Block 7) may support recovery.